MassChallenge

Omny, Inc. is a technology company that specializes in developing an interoperable distributed ledger platform tailored for the pharmaceutical, biotechnology, and life sciences sectors. Founded in 2017 and based in Belmont, California, the company’s platform enhances the visibility and management of healthcare data by integrating with legacy systems and providing a secure, immutable chain of custody for real-time multiparty audits. This allows all network participants to maintain ownership of their data. Additionally, Omny offers a Dashboard feature that tracks data provenance in real time, delivering critical insights for business decision-making. The platform aims to create a connected ecosystem that facilitates collaboration among patients, providers, and life sciences organizations, thereby promoting scalable partnerships and fostering patient-centered, evidence-based care.

Selmod provides development of innovative small molecule therapies for the treatment of life-threatening invasive fungal infections.

Netnoids Rx Laboratories operates a cancer contract research organization that uses patient-derived organoid model systems to help find a cure for rare cancers.

MediCircle utilizes technology to eliminate barriers to care and reduce pharmaceutical waste. The company collects leftover oral chemotherapeutics, ensures the medicine’s quality, and redistributes it to those in need. Its advanced technology allows them to offer a safe, low-cost alternative to disposal. MediCircle creates significant savings for patients, insurance companies, and healthcare facilities, all while improving the health of its local communities.

AMF Medical, based in the EPFL innovation park in Switzerland, specializes in designing high-end, user-friendly fluidic solutions, particularly in automated liquid handling systems. The company emerged when partners involved in a complex lab automation project sought suitable components that were unavailable in the market. Recognizing their expertise in microfluidics, AMF Medical collaborated with these partners to create tailored solutions, resulting in the development of their first product, the automated sample preparator. The company is dedicated to advancing the field of microfluidics by providing innovative and effective solutions for laboratory automation.

ModoScript develops a B2B hardware SaaS solution aimed at enhancing remote treatment monitoring through big data analytics. The company focuses on high-price specialty pharmaceuticals, particularly Oral Oncolytics, to improve treatment outcomes by collecting and analyzing health data. This approach allows for the development of more personalized and safer therapies while facilitating better at-home care. ModoScript targets pharmaceutical companies, health insurance providers, and physician groups, and partners with mail-order specialty pharmacies and in-office pharmacies for distribution. The company's mission is to provide a customizable data analytics model that improves patient outcomes and enables access to its solutions at no cost for patients. By prioritizing chronic disease patients, ModoScript aims to ensure high-quality remote care that is equitable, regardless of race, condition, or socioeconomic status.

Uniphage is a biotech company that eliminates bacterial infections by combining the power of bacteriophages with artificial intelligence. Their first target disease is citrus greening, an incurable and debilitating disease that costs the United States more than $2 billion each year. Uniphage created the first commercially effective models for computationally predicting safe bacterial viruses against target bacterial infections, as well as discovered a variety of targets. This enables them to deliver new antimicrobial, safe, and precise products to market much more quickly.

Insu Health Design develops a personal-use system for storing medicines. The storage integrates a thermoelectric cooler, vacuum flask, and fluid loop to keep medicine cool for long. It includes inexpensive solar panels and a portable, battery-powered cooler with multiple charging options, enabling patients who use bio-medicines like insulin to protect their health by preventing it from spoiling during times of travel, power outages, or disaster situations. Mason Lucich and Doris Candelaria co-founded the company in San Juan, Puerto Rico in 2018.

AcousticaBio is a biotechnology company focused on reformulating intravenous medications for subcutaneous delivery. The company has developed a fluid processing technology that creates complex microparticles, enabling the conversion of biologic products typically administered intravenously into highly concentrated, small-volume injections suitable for under-the-skin administration. This innovative approach allows patients to self-administer essential medications with less pain and discomfort, reducing the need for lengthy hospital visits and enhancing overall patient convenience.

Glamorous AI is a developer of an artificial intelligence-based drug discovery platform. The company's platform specializes in the research of medicines from the preceding experimental results, identifies and assimilates multiple subtle and complex compounds.

Asan Therapeutics utilizes a novel technology that simplifies the treatment of cancer patients to receive only a single injection instead of several painful injections.

NERAMCO develops smart polyethylene fibers and fabrics, SVETEX, for the textile industry. SVETEX materials have superior functionality and can be used as a sustainable/recyclable material that reduces water consumption and pollutants. The company develops apparel for children with skin disorders, and temperature-reducing underwear for menopausal women (for comfort) and all men (for improved fertility).

Transcera is a biotechnology company focused on advancing the treatment of chronic diseases through innovative drug delivery systems. It has developed a novel lipid-based platform that enhances the targeting and absorption of therapeutic molecules, allowing larger drugs to effectively cross cellular barriers. This approach aims to improve the pharmacokinetics of treatments, ultimately benefiting patient outcomes by ensuring that medications are delivered more precisely and efficiently. Transcera's technology represents a significant advancement in drug delivery, addressing critical challenges in the management of chronic conditions.

BestHealth4U focuses on researching and developing advanced medical adhesive technologies aimed at enhancing patient care. The company creates innovative and eco-friendly adhesive solutions designed to prevent skin injuries, accelerate healing, and improve overall patient health. By transforming the attachment methods for bandages, dressings, and medical devices, BestHealth4U enables healthcare providers to minimize skin damage, discomfort, irritation, and the risk of infection. The company's commitment to safe and effective products supports doctors in preventing adhesive-related skin injuries, ultimately promoting better patient outcomes.

Michroma Corporation is a biotechnology company based in San Francisco, California, founded in 2019. The company specializes in producing natural thermostable colorants derived from filamentous fungi, aiming to replace synthetic and non-sustainable colorants commonly used in food and cosmetics. By leveraging a fermentation process and utilizing colorful fungal strains, Michroma provides a diverse array of pH-stable and heat-stable natural pigments. This innovative approach not only supports sustainability but also caters to the growing demand for vegetarian and environmentally friendly alternatives in the food industry.

FermBiotics is a microbiome company dedicated to enhancing gut health globally. The company specializes in the development of sustainable, fermented plant and seaweed ingredients that serve as food components, dietary supplements, and medical foods. By integrating prebiotics, probiotics, and bioactive compounds, FermBiotics has created a novel category of fermented products aimed at promoting a positive gut microbiome. This innovation supports both human and animal health, enabling families and pet owners to assist the elderly and their animals in maintaining optimal gut health.

Developer of fluidic devices intended to improve the effectiveness of laboratory tests, experiment with innovative therapeutic approaches and reduce animal testing. The company's device includes a wide set of applications, such as cosmetics, oncology and pharmaceutical, toxicology and pollution, nutraceutical and agri-food, enabling clients to cultivate three-dimensional tissues, similar to human ones, in clinically relevant dimensions on which to operate in vitro tests and take decision accordingly.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015, that focuses on developing medical devices for blood type analysis and disease detection. The company's flagship product, also named Criam, enables rapid and affordable blood test analysis, allowing users to receive immediate information about their health. This medical device can detect various diseases, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. By positioning itself in the Point-of-Care diagnostic segment, Criam aims to empower individuals with timely health information and contribute to the global monitoring and control of diseases.

Pacify Medical Technologies is a medical device startup with patent-protected technology that sprays skin tissue on wounds for fast recovery.

Developer of an aqueous technology platform designed to deliver ultra-low friction and efficient lubrication relevant to various medical and technological applications. The company specializes in using hydration water as the lubricating element which spontaneously adsorbs and coats biological as well as artificial surfaces, enabling healthcare and pharmaceutical professionals to coat biological surfaces and also provide the vehicle to encapsulate active pharmaceutical ingredients or supplements and to deliver these to targets that currently are difficult to reach.

EcoPhage, a biotech company, leverages a disruptive technology for using viruses that attack bacteria (bacteriophages) for crop protection. Its unique approach allows for high throughput screening and cocktail optimization to deliver the most efficient and efficacious phage-based products in crop protection. Farmers’ need for effective, environmentally friendly solutions to combat bacterial diseases in crops prompted the effort to seek additional approaches. Bacteriophages have been recognized as natural enemies of bacteria for decades; yet, there has been a lack of technology for pinpointing the “right” phage combination to effectively fight disease, which inhibited acceptance for applications in agriculture. The company was founded in 2019 and is based in Ness Ziona, Israel.

Lyfegen HealthTech AG, founded in 2018 and based in Basel, Switzerland, provides a healthcare platform that focuses on automating value-based healthcare contracting. The company's technology enables life sciences companies, healthcare payers, and providers to collect, analyze, and reconcile diverse healthcare data. By streamlining these processes, Lyfegen facilitates personalized healthcare through patient-level pricing and enhances access to treatments for patients. Their solutions aim to improve health outcomes and affordability across the healthcare sector, supporting clients in implementing effective value-based healthcare strategies.

knowRX™is a mobile online application that schedules, monitors, and provides feedback on drug usage (prescription and over-the-counter medicines) for consumers and designated medical contacts. knowRX™ promotes wellness, accountability, and consumer feedback throughout the completion of a course of therapy. knowRX™ is designed to promote well-being through an online platform for patient and physician engagement. The Platform provides important drug information and current clinical trial reports to assist healthcare providers and their patients in the selection of the right therapy for the individual. Additionally, through this user-friendly app, patients are offered access to counseling, genomics data for treatment compatibility, nutritional guidance, holistic insights, clinical trial opportunities and instructional videos on clinical research, and trending analysis regarding medication behavior, all with the goal of achieving the most beneficial treatment outcomes. The makers at knowRX™ recognize that drug adherence is a major factor in the success of medical therapy. There is no single solution that addresses nonadherence for all patients. We set out to create an interactive platform that makes available multiple solutions and learns about consumers to establish and refine access to tools that best fit the respective needs of individual patients.

Naturbeads, a company working to manufacture a replacement ato the ocean-polluting microbeads that, despite initial bans in “rinse-off” cosmetics, are found in many personal and home care products and paints. Naturbeads manufacture a biodegradable alternative to plastic microbeads that could reduce micro plastic pollution in the oceans. The technology to create the cellulose microbeads was developed at the University of Bath by Professors Janet Scott and Davide Mattia from the Centre for Sustainable Chemical Technologies in 2017

Developer of nanotechnology intended to solve challenges across medicine and other industries. The company uses different types of biomaterials as building blocks and has fabricated diverse types of systems such as nanoengineered hydrogels, nanosized molecular delivery systems, and nanocomposite materials, helping businesses across different industries to use nanotechnology and grow their business.

Developer of drug delivery solutions intended to facilitate enhanced absorption of co-administered therapies. The company offers novel drug delivery solutions built around its proprietary permeation enhancer, being able to replace current intravitreal injections of biologics with eye drops, enabling users to get patient safety, patient compliance, and decreased health care costs.

OrganoTherapeutics is a company focused on developing medical drugs aimed at treating Parkinson's disease. It utilizes advanced human-specific mini-brain models that accurately replicate the pathology of Parkinson's disease for the discovery and development of effective drug candidates. By employing three-dimensional models derived from both healthy individuals and patients with Parkinson's disease, OrganoTherapeutics identifies the therapeutic potential of various compounds and analyzes data using artificial intelligence. This innovative approach facilitates the screening of new molecules, allowing researchers to advance novel drug candidates. The company has already developed proprietary drug candidates and has access to extensive libraries for further research and development.

Octarine Bio is a biotechnology company based in Copenhagen, Denmark, founded in 2018. The company specializes in the research and development of cannabinoid and psilocybin derivatives using synthetic biology. By employing a biosynthetic platform, Octarine Bio aims to create a range of natural and novel cannabinoid and psilocybin-derived molecules that possess enhanced pharmacokinetic and therapeutic properties. These advancements are designed to support healthcare professionals in treating neurological and psychological disorders, ultimately improving the health and well-being of individuals.

Operator of an innovative deep learning and analytics platform intended for life sciences and healthcare organizations. The company's scalable deep learning software provides dark data analytics, cortex chemvector, neural concept recognition, secure cloud deployment, collaborative analytics, and project-based deep learning, enabling life sciences and healthcare organizations to apply deep learning analytics to enterprise data.

Bloomsbury AI uses Artificial Intelligence and Big Data to identify new indications for existing drugs, reduce the time, cost, and risk in drug discovery.

Manufacturer of photocatalysis-based technologies intended to remove per and poly fluoro alkyl substances. The company's platform breaks down toxic PFAS and eliminates them from the ecosystem by removing toxic chemicals from water, enabling water utilities and manufacturers to cost-effectively remediate PFAS and meet regulatory requirements.

ChondroNest is focused on developing medical technologies aimed at cartilage reconstruction, specifically targeting conditions such as Osteochondritis and Osteoarthrosis. The company is creating a device made from modified biopolymers intended for in vivo use, facilitating easier and more effective reconstruction surgeries for surgeons. ChondroNest plans to conduct preclinical tests on animal models before moving on to human trials. Following these initial trials, the company intends to license its product to major MedTech companies for sales and marketing purposes, while maintaining control over the production of its ChondroNest™ pastes.

Developer of a technology platform designed to improve the processes of drugs that are drawn at the point of care. The company's platform allows users to streamline the processes associated with preparing, administering, and documenting drugs that are drawn on-demand at the point of care, helping hospitals capture significant lost revenues from insurance companies, reduce non-compliance exposure, and increase patient safety.

Medical Elution Devices features polymer-coated devices containing medication(s) that is engineered to adhere to the surface of existing chest tubes, endotracheal tubes, implants, etc., and elute drug over a pre-determined period.

Developer of a peptide and protein purification technology designed to revolutionize recombinant production processes. The company's technology facilitates the production of enhanced purity products, significantly diminishing the purification challenges prevalent in modern chemical (peptide synthesis) and biological synthesis (recombinant) methods to meet specific requirements, enabling clients to efficiently overcome purification and economy-to-scale obstacles encountered in stock breeding.

Sano Chemicals is an early stage biotechnology company primarily focused on the development of novel anti-infectives for clinical and agricultural use. The word “Sano” is derived from the Latin word meaning health, thus, they are focused on the development of products that will promote their health and a healthy and sustainable environment. Sano Chemicals is focusing on the development of antifungal treatment options for fungal infections and antifungal bio-control methods for crops. Their goal is to innovate the anti-fungal industry. The antifungal occidiofungin is a completely unique antifungal compound discovered by researchers at Mississippi State University and Texas A&M University. Novel applications in occidiofungin's use are being developed through the innovative endeavors of their scientists. Products that cure fungal infections (nail, skin, and systemic), as well as products that promote a sustainable food supply by targeting fungal diseases in plants are being developed.

Phytolon Ltd, located in Misgav, Israel, specializes in the development of technology for producing natural food colorants. Founded in 2000, the company utilizes baker's yeast cells as bio-factories to create these colorants through a fermentation process. Phytolon's innovative approach aims to provide sustainable and natural alternatives for the food and beverage industry, addressing the growing demand for clean-label products.

Parx Plastics recognized a growing demand for plastics with antibacterial/antimicrobial properties and from their expertise they knew that the available solutions to achieve such materials were not suitable for large-scale application/adoption because of their possible harmful effects on humans, animals or the environment as a whole. They had foreseen the dangers, insecurities and disadvantages of these solutions. Over four years of dedicated biomimetic research has been invested to create a 100% safe and biocompatible technology to inhibit the growth of bacteria on the surface of plastic with the use of a Biomimetic approach in the design and engineering of the materials. The discoveries and inventions done during this research are truly unique and groundbreaking. A team of 11 professors, scientists and researchers with decades of experience in the field of Nano- and biotechnologies and skilled in chemical analyses and chemical-physical and microbial analyses have been working together with a renown European university for chemistry. The result is a worldwide patent-pending innovation for highly effective plastics with an antibacterial/antimicrobial effectiveness rate of 98-99% measured according to ISO 22196 and most of all: safe. Parx Plastics Sanipolymers are safe for humans, safe for animals and safe for the environment.

Developer of nanotechnology intended to solve challenges across medicine and other industries. The company uses different types of biomaterials as building blocks and has fabricated diverse types of systems such as nanoengineered hydrogels, nanosized molecular delivery systems, and nanocomposite materials, helping businesses across different industries to use nanotechnology and grow their business.

Tellus Therapeutics is a biopharmaceutical company focused on creating innovative treatments for newborns facing perinatal brain injuries. The company specializes in developing small molecules derived from human maternal breast milk, which aim to promote the regeneration of myelin-producing oligodendrocytes and mitigate white matter injury in premature infants. By addressing unmet medical needs, Tellus Therapeutics enables healthcare providers to offer effective interventions for all babies at risk of brain injury, thereby improving neurodevelopmental outcomes for these vulnerable children.

InvivoSciences specializes in phenotypic compound screening services that enhance drug discovery and repositioning. The company employs an innovative approach that combines tissue engineering technology with assay automation and sample miniaturization, facilitating rapid and cost-effective therapeutic discovery. Its mission focuses on developing engineered tissue-based assays that closely replicate the functions of living organisms, including humans and animals. By integrating patient-derived and gene-edited human samples, InvivoSciences aims to personalize the drug development process. The company utilizes advanced techniques in cell and tissue handling, tissue phenotyping assays, and computational biology, including artificial intelligence, to assist clinicians in swiftly identifying the safety and efficacy of treatments tailored to specific patient groups, thereby optimizing the preclinical phase before embarking on costly clinical trials.

Developer of an antibody drug discovery platform designed to reprogram cancer cells to treat advanced cancers to be centered around proprietary artificial intelligence. The company's platform designs custom antibodies with high selectivity and specificity linked to proprietary cellular reprogramming lab assays, its drugs modulate activities of a novel set of growth factors called dual smad inhibiting protein dips, thought to drive the growth and spread of cancer, enabling physicians to get access to novel drugs in areas of unmet medical needs.

Aniluxx Biotechnology is a development stage biopharmaceutical company with a mission to improve companion animal health and well-being. The Company’s strategy is to translate its deep pipeline of topically formulated therapeutics, predicated on compounds that have already been identified as safe and effective in humans, into therapies for dogs, cats, and horses, that are easy to apply, virtually unnoticeable, and absent the harsh side effects of systemic medicines.

Medical Apparel

Virtual is a developer of prescription digital therapeutics platform intended to help mental health treatment. The company's tool adheres to strict compliance with FDA quality management standards and also is put through rigorous research trials and in certain cases is paired with existing pharmacological treatments, as well as uses virtual reality to administer VR exposure therapy, assign CBT assessments or exercises and track patient progress, enabling patients to overcome anxiety, phobia and obsessive-compulsive disorder easily.

Virtual is a developer of prescription digital therapeutics platform intended to help mental health treatment. The company's tool adheres to strict compliance with FDA quality management standards and also is put through rigorous research trials and in certain cases is paired with existing pharmacological treatments, as well as uses virtual reality to administer VR exposure therapy, assign CBT assessments or exercises and track patient progress, enabling patients to overcome anxiety, phobia and obsessive-compulsive disorder easily.

Tellus Therapeutics is a biopharmaceutical company focused on creating innovative treatments for newborns facing perinatal brain injuries. The company specializes in developing small molecules derived from human maternal breast milk, which aim to promote the regeneration of myelin-producing oligodendrocytes and mitigate white matter injury in premature infants. By addressing unmet medical needs, Tellus Therapeutics enables healthcare providers to offer effective interventions for all babies at risk of brain injury, thereby improving neurodevelopmental outcomes for these vulnerable children.

Developer of neurological disorders therapy designed for critical mediators of inhibition within the brain. The company's platform has developed a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery engine to improve the lives of people suffering from neurological disorders by fine-tuning inhibition to treat conditions such as epilepsy, pain, and other central nervous system pathologies, thereby enabling the healthcare industry to resist neurodegeneration, restore excitation, and regenerate neurons.

Producing an effective chemotherapy solution with a fully automated tumor-on-a-chip, pre-prescription analysis.

Developer of a health platform designed to address preventable and costly adverse drug reactions(ADR). The company's platform enabled with data analytics utilises user input data and data from qualified databases like the government databases to identify ADR trends, risks, and decision point failures, enabling patients can make informed decisions and take charge of their health.

EMet Nanotech specializes in advanced nanofabricated chip technology that enhances the cryo-electron microscopy (cryo-EM) sample preparation process, making it significantly faster and more efficient. By utilizing their innovative PicoCell, a one-step freezable imaging grid, the company streamlines the sample preparation that traditionally requires multiple steps and expensive robots. This technology not only reduces costs and time but also improves reproducibility in drug discovery, enabling biopharmaceutical companies to better understand diseases and develop effective therapies. EMet Nanotech's solutions aim to accelerate the development of new treatments in the biopharma sector, ultimately contributing to advancements in healthcare.

XELPHAhealth's is a modern solution that enables medical facilities to overcome operational efficiencies and increase the adoption of electronic medical record technology. Through the interlacing of technology, innovative business models, and value-based healthcare, XELPHAhealth is addressing the unique challenges of healthcare delivery. XELPHAhealth is device agnostic, cloud-based, scalable platform, that offers a comprehensive solution by integrating clinical and ancillary modules to deliver superior care while lowering operational cost.

Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe bacterial infections and combat antibiotics resistance.

Reboot Rx is a nonprofit health tech startup dedicated to fast-tracking the development of affordable cancer treatments using repurposed generic drugs, AI technology, and innovative funding models.

Operator of an environmental testing biotechnology company intended to ensure the safety of each chemical studied to protect human and environmental health. The company focuses on the development of technologies to analyze chemicals such as pesticides and consumer goods for bio-accumulation potential and utilizing in vitro technology to test for bioaccumulation to reduce both cost and experimentation time, enabling customers to deliver the quality service to ensure human and environmental health protection.

Hempfy focuses on innovative food and beverages, based on proprietary cold infusion technology for harvesting and processing THC-free hemp plants, compliant with Swiss legislation. All their products are 100% Swiss made : they grow Hemp, produce and develop their products exclusively in Switzerland from bottom to top. Their production is based on bespoke quality, starting from selecting the best seeds, clearest spring water till final production by the very "Swiss way of doing things".

Manufacturer of agricultural chemicals intended to make the planet healthier by replacing chemicals used in conventional agriculture. The company's chemicals are used to stimulate plant and vegetable growth, improve absorption of nutrients through the roots, strengthen photosynthesis, and increase the number of useful microbes, enabling farmers to increase their crop product and quality.

Microcaps AG specializes in developing innovative microencapsulation technology that facilitates the precise fabrication of monodisperse capsules and microparticles. Founded in 2018 and based in Zurich, Switzerland, the company focuses on scalable production through microfluidics, which allows for enhanced size control, precise dosing, and increased stability of microcapsules. Its technology is particularly beneficial for protecting pharmaceutical agents in drug delivery and encapsulating probiotics. Microcaps provides tailored solutions that significantly improve throughput rates and maintain quality, surpassing conventional production methods. The company's aim is to establish a fully-automated encapsulation micro-factory that streamlines the manufacturing process and meets the diverse needs of its clients in pharmaceuticals and cosmetics.

CrystalsFirst GmbH, founded in 2018 and based in Marburg, Germany, specializes in developing innovative methodologies for protein crystal stabilization aimed at accelerating drug candidate screening. Its proprietary SmartSoak technology allows for the screening of small molecule arrays to identify novel lead candidates through the use of stabilized protein crystals. The company also offers SmartLib, a compound library for fragment-based drug discovery, and SmartRefine, software designed for the automated refinement of crystallographic diffraction data. CrystalsFirst enhances the drug discovery process by creating high-resolution 3D models that elucidate the interactions between proteins and drug candidates. By integrating high-performance crystallography with chemoinformatics and AI, the company focuses on developing therapeutics in oncology and hematology, thereby addressing the growing demand for bio-structural data and significantly accelerating innovation cycles in the biopharmaceutical industry.

SiNON is dedicated to improving the lives of those who suffer from debilitating neurological diseases by increasing the ability of drugs to cross the Blood Brain Barrier (BBB).

Resistell is a antibiotic resistance test.

BASF is a global chemical company headquartered in Ludwigshafen, Germany, operating through six primary segments: chemicals, plastics, performance products, functional solutions, agricultural solutions, and oil and gas. The company produces a diverse range of products, including basic chemicals, engineering plastics, and specialty materials for various industries such as automotive, construction, and pharmaceuticals. In addition to its core activities, BASF New Business GmbH actively seeks to identify and explore new industrial opportunities, focusing on innovative solutions in chemistry and sustainability. BASF Venture Capital GmbH, the company's investment arm, invests in startups and venture capital funds that align with BASF's strategic interests, emphasizing advanced materials and digitalization, among other fields. The company also has a subsidiary, BASF West Africa Limited, which manufactures construction chemicals in Nigeria. With a commitment to innovation and sustainability, BASF aims to address significant challenges faced by customers in both existing and emerging markets.

Developer of a novel drug therapy designed to treat and prevent recurrent kidney stones. The company's therapy is derived from a gut bacterium to prevent and treat kidney stone diseases such as hyperoxaluria and oxalate-based kidney stones as well as renal diseases caused by high levels of oxalate in the body, thereby enabling patients to receive quality drug therapy in order to remove oxalate safely from the body and consequently prevent recurrence of stones.

MicroQuin is a biotechnology company founded by Dr. Scott Robinson and Yang Zheng, focused on developing innovative therapeutics to tackle significant diseases, particularly cancer. The company has created a targeted delivery platform for chemotherapy that selectively directs treatment to cancer cells while sparing healthy cells from toxicity. This approach involves binding to cancer cell surfaces, disrupting cellular structures, and promoting cell death, thereby enhancing the efficacy of existing chemotherapeutic agents for various cancers, including breast, lung, prostate, ovarian, and melanoma. MicroQuin has received recognition as a finalist in the 2018 MassChallenge and as a winner of the CASIS/Boeing Prize, which supported research conducted on the International Space Station. The company is headquartered at LabCentral in Cambridge, Massachusetts.

Aspivix SA, based in Lausanne, Switzerland, specializes in the development of innovative surgical instruments for gynecology, focusing on enhancing patient comfort during procedures. Founded in 2015, the company has created a patented, disposable device that employs gentle vacuum suction to stabilize the cervix, replacing traditional sharp-teeth forceps. This approach not only minimizes pain but also significantly reduces the risk of lesions, bleeding, and cross-infections. The technology enables physicians to perform gynecological procedures more safely and effectively, improving overall patient care.

Developer of a medical device designed to dispense pills and monitor daily dosage for long periods of medication. The company's devices support real-time monitoring services with built-in cellular connections which increases compliance, enabling doctors and patients to remotely track the medication course.

ALAnostics is a speciality Biopharmaceutical company, and a spin-off from the University of Geneva, developing tumour paint to help surgeons identify and remove breast cancer in real-time during breast cancer surgery.

Nagi Bioscience SA, based in Lausanne, Switzerland, specializes in the development and manufacturing of an innovative automated testing device that utilizes Caenorhabditis elegans, a type of microscopic worm, for the assessment of substances in pharmaceutical, chemical, and cosmetic industries. This technology, known as "Organism-on-Chip," integrates in vivo testing with a fully automated in vitro platform for handling, culturing, and analyzing these organisms. Nagi Bioscience's solutions facilitate toxicity testing, drug discovery, and anthelmintic testing, allowing clients to gain insights into the complete biological responses that can only be observed at the organism level. This approach aims to transform traditional methods of evaluating the toxic or beneficial effects of various substances.

Developer of an organs-on-chips system designed to revolutionize pharmaceutical development and personalized medicine. The company's systems use origami folding to convert easy-to-manufacture, 2D patterns into complex, 3D tissue architectures, thereby enabling clients to advance the development of pharmaceutical, chemical, food, cosmetic, and personalized medicine products.

Pilleve is focused on addressing the critical issue of opioid addiction, which has significantly impacted public health in the United States. By developing an integrated pill bottle and a smartphone application, Pilleve enables real-time monitoring of prescription opioid intake. This system requires patients to input passwords or use biometric scanners for pill dispensing and prompts them to report their pain levels and mood before taking medication. This approach allows for early detection of potential misuse and enables timely intervention by healthcare providers. Physicians receive alerts if patients exceed recommended dosages, allowing them to adjust prescriptions or implement strategies to help patients reduce their reliance on opioids. By facilitating behavioral analysis and providing access to a support network, Pilleve aims to reduce the social and financial burdens associated with opioid misuse, benefiting patients, healthcare providers, and insurance companies alike.

Developer of surface coating technologies designed to improve the biocompatibility and performance of implanted devices and biosensors. The company's technology permanently modifies implanted devices and biosensors to improve biocompatibility and reduce infections, coatings are long-lasting and do not interfere with the sensitivity of biosensors, enabling users to use biosensors that have limited biocompatibility and are prone to infection.

Canomiks provides a genomics, bioinformatics and AI-based Product Superiority Platform that enables companies within the functional food and beverage, dietary supplement and skincare industries to create safe and efficacious products. Canomiks' long-term vision is to make food as medicine a reality.

ReviveMed Inc is a precision-medicine company based in Cambridge, Massachusetts, founded in 2016. It specializes in a platform that harnesses data from small molecules, or metabolites, to generate actionable insights. The company's technology employs a network-based machine learning algorithm for the integrative analysis of untargeted metabolomic data alongside other extensive molecular information, such as data from genes, proteins, drugs, and diseases. This innovative approach enables researchers to develop in-house therapeutics specifically aimed at treating patients with liver diseases and related conditions, ultimately aiming to improve overall health outcomes.

Keheala is a healthcare company based in Tel Aviv, Israel, founded in 2014. It focuses on developing a mobile software ecosystem aimed at reducing drug non-compliance, particularly in the context of infectious and chronic diseases. The platform delivers behavioral interventions through mobile devices, enhancing healthcare access and improving treatment outcomes for patients in the developing world. By providing healthcare practitioners with valuable insights, Keheala plays a crucial role in supporting better adherence to treatment, ultimately contributing to improved health outcomes and saving lives.

BlockMedx, LLC, founded in 2017 and based in Austin, Texas, has developed a secure, HIPAA-compliant e-prescribing and analytics ecosystem. This system facilitates the transmission of electronic prescriptions, including DEA Controlled Drug prescriptions, from physicians to pharmacies using the Ethereum blockchain. In addition to its core e-prescribing capabilities, BlockMedx's platform also predicts patient risk behaviors and promotes healthy habits through an internal token economy. By leveraging advanced technology, BlockMedx aims to enhance the safety and efficiency of the prescription process while addressing public health concerns related to prescription medications.

EllieGrid Inc. specializes in medication management solutions, offering both hardware and software products to assist individuals and families in organizing their medications. The company has developed a Bluetooth-enabled pill box designed to help users stay on schedule with their medication routines. Complementing this, EllieGrid provides a mobile application that enables users to program the device, receive timely notifications for medication intake, and manage a comprehensive list of their medications. Additionally, the platform collects compliance data, which is accessible to caregivers and healthcare providers, facilitating timely interventions when necessary. Founded in 2015, EllieGrid is headquartered in Austin, Texas, and sells its products online.

Vigilant Waste is a company focused on enhancing safety in healthcare environments by addressing the risk of opioid addiction among hospital staff. It has developed an automated waste management platform specifically for controlled substances, which eliminates the need for human witnesses during the disposal process. This system verifies the composition and volume of each waste dose at the point of use, effectively reducing the potential for drug diversion. By implementing this technology, Vigilant Waste aims to create a safer workplace for medical staff and mitigate the risks associated with opioid misuse in hospitals.

Newormics is a developer of the first high-throughput, high-content drug screening platforms for use with in vivo small animal models as well as in vitro 3D tissue constructs. The company provides proprietary microfluidics-based platforms to advance early stage drug discovery and toxicity studies for faster and better drug development with cost-effective solutions.

Bezoar Laboratories focuses on enhancing health for humans, animals, and the environment through innovative microbial solutions. The company develops probiotic medical and pharmaceutical products specifically designed to alleviate gastrointestinal issues, including bloating, constipation, and diarrhea. Their offerings are formulated to be free of gluten and dairy, and they maintain a low acidity level to ensure safety and effectiveness for consumers. By addressing these common health concerns, Bezoar Laboratories aims to improve overall well-being and promote healthier living.

Diffregen is a startup focused on development of new leukemia drug candidates. Their active ingredients are based on Angiocidin, a protein which has been shown to activate monocytes and drive terminal differentiation of leukemia cells.

At Halo Life Science their aim is to Elevate Human Potential. After 3 years of research and development they are pleased to announce their initial, patent(s) pending product Naturalin™ - a phytonutrient that puts health and wellness into everything you eat and drink. Naturalin will also come in nutritional supplement forms. Validated safe, functional, and effective by researchers at the Dell Pediatric Research Institute at The University of Texas at Austin. Their mission is to deliver safe, effective, simple, affordable, accessible food and nutritional supplement products to everyone, everywhere.

Octagon Therapeutics, a preclinical-stage biopharmaceutical company developing antibiotics for multi-drug resistant infections, Octagon has demonstrated effectiveness against the most critical pathogens as identified by the WHO. Octagon World Headquarters is based in the Pagliuca Life Lab directly adjacent to Harvard campus. This state-of-the-art facility has allowed Octagon to accelerate the development of our vital medicines with minimal overhead and equipment costs. Octagon’s management team includes highly skilled scientists, clinicians, and entrepreneurs with decades of research experience and deep expertise in drug development. The scientific team is growing and continues to add top research talent.

Cam Med LLC, founded in 2014 and based in West Newton, Massachusetts, is a development-stage company focused on creating innovative drug delivery devices utilizing microfluidics technology. The company's flagship product, Evopump, is a bandage-like patch pump designed for the subcutaneous delivery of one or more medications. By prioritizing patient-friendly designs and precision in drug administration, Cam Med aims to significantly enhance the daily lives of patients requiring medication delivery solutions.

Epharmix, Inc. is a digital healthcare company that specializes in developing clinically validated, condition-specific communication tools for the healthcare industry. Founded in 2015 and based in Saint Louis, Missouri, Epharmix provides digital interventions designed to enhance patient-physician engagement, automate the collection of clinical data, and alert healthcare providers for effective chronic care management. Its products aim to improve care for underserved patients while also reducing the workload of care teams, ultimately enhancing patient engagement and health outcomes.

Pillo, Inc. designs and develops a digital care management platform that provides health care plans for adults with chronic conditions at home. The company offers Pillo, a robot, which enable people to manage their health; answer health and wellness questions; connect with healthcare professionals; manage vitamins and medication; and store, dispense, and order refills when required. The company’s robot also sends notifications to the user when medications are missed; sees and hears user to keep them healthy and safe; and syncs with wearables and smart home devices. Pillo, Inc. was incorporated in 2015 and is based in New York, New York.

Adeo Health Science, Inc. is a Boston-based company that develops and produces organic food products designed for special dietary needs, particularly for infants. Its flagship product, Aralyte, is an organic food that incorporates natural distilled peanut extract and Vitamin D, helping parents implement the LEAP regimen to prevent peanut allergies in babies starting solid foods. Founded in 2014, the company emphasizes biotechnology and translates the latest food allergy prevention research into user-friendly and trusted products for families. Adeo Health Science is committed to providing non-GMO options that support informed dietary choices for children's nutrition.

VeriPAD is a startup focused on combating the widespread issue of counterfeit medications, particularly in low- to middle-income countries where a significant percentage of drugs may be fake. The company has developed a counterfeit drug detection platform that automates the authenticity testing of medications, including amoxicillin and pravastatin, to help reduce the risks associated with counterfeit drugs. Their solution features a testing kit that uses chemically pre-treated paper that changes color upon contact with a drug, along with a smartphone application that alerts users to the authenticity of their medications. By empowering patients with accessible and accurate technology, VeriPAD aims to raise awareness about counterfeit medications and improve health outcomes for millions affected by this critical issue.

Torigen Pharmaceuticals is dedicated to advancing immuno-oncology solutions for companion animals facing cancer. The company develops innovative immunotherapy treatments, notably an experimental autologous cancer vaccine that activates the immune system to target specific tumor-associated antigens. This approach allows for the detection and treatment of cancer without relying on invasive surgeries or chemotherapy, thereby improving the quality of care for animals. By leveraging years of scientific research, Torigen Pharmaceuticals aims to provide effective and less painful options for veterinary oncology, positioning itself at the forefront of cancer treatment for pets.

IbtiCare has invented an innovative antibacterial technology based on Physical Vapor Deposition (PVD). This cutting edge technology can coat many surfaces with advanced nanoparticles and make them antibacterial against all types of dangerous bacteria that are resistant to any drugs. From many aspects, technology is superior compared to the current antibacterial methods. Their antibacterial technology has passed clinical trials and has been validated by operating leaders in healthcare.